Key result
Pharmacogenetic testing shows high yield for identifying clopidogrel resistance in outpatient stroke patients.
Answers are grounded in this paper and cite their sources.
Supports targeted testing in stroke outpatients; leaves open whether it improves secondary prevention outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ala et al. (2026) studied this question. Pharmacogenetic testing demonstrated a high yield for identifying clopidogrel resistance in a Canadian outpatient stroke population.
Synapse has enriched 10 related papers. Consider them for comparative context: